Keytruda Lung Cancer - Search News

BioNTech to buy Biotheus, gaining control of cancer bispecific

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab over Keytruda.

Business Insider · 4h

BioNTech to acquire Biotheus for upfront consideration of $800M

BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology

MarketWatch · 12h

BioNTech to Acquire Biotheus in $950 Million Deal

The tie-up will also expand BioNTech's footprint in China, giving it a local research and development hub for clinical trials, as well as a new biologics manufacturing facility and more than 300 Biotheus employees,

Reuters on MSN · 12h

BioNTech buys China's Biotheus to support oncology strategy

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.

Business Insider · 10h

BioNTech to Acquire Biotheus to Boost Oncology Strategy

Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational

Cure Today1d

Jemperli-Chemo Regimen Shows Survival Promise in Advanced NSCLC

Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS ...

pharmaphorum5d

'Keytruda is King' in lung cancer, putting BMS and next-gen in the shade

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

GlobalData on MSN15d

Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer

Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...

FierceBiotech17h

BioNTech pays $800M to take control of potential Keytruda killer

If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... bispecific antibody in combination with chemotherapy in ...

MM&M2h

BioNTech spends $800M upfront to pick up China-based Biotheus

Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

Cure Today13d

First Patients Dosed in Three Trials Assessing Dato-DXd-Based Regimens in Lung Cancer

Three phase 3 trials will assess datopotamab deruxtecan-based treatments in patients with nonsquamous non-small cell lung ...

PMLiVE22d

Merck’s Keytruda recommended by NICE to reduce risk of lung cancer recurrence

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small ...

Daily10d

Merck, Moderna begin Phase 3 Trial of V940 with Keytruda in non small lung cancer

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

16d

Why Is Moderna Stock Trading Higher On Monday?

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results